Kiniksa Pharmaceuticals International (KNSA) Earnings Analysis
Kiniksa Pharmaceuticals International (KNSA) has no confirmed upcoming earnings date. Last quarter (2024-07-23) it beat with EPS -0.06 USD vs -0.09 USD est (+33.3%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 63.71.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KNSA next report earnings?
No confirmed upcoming earnings date is currently scheduled for KNSA. This page updates as the calendar is published.
KNSA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-07-23 | -0.06 USD | -0.09 USD | +33.3% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
KNSA valuation and analyst view
| Trailing P/E | 63.71 |
|---|---|
| Trailing EPS | 0.9548 USD |
| Price / book | 7.89 |
| Dividend yield | 0.00% |
| Market cap | 4.65B |
| Analyst consensus | Buy (11 buy / 0 hold / 0 sell) |
| Avg price target | 70.2 USD |
Related research pages
Frequently asked questions
When is Kiniksa Pharmaceuticals International (KNSA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for KNSA. This page updates as the calendar is published.
Did KNSA beat earnings last quarter?
In its 2024-07-23 report, KNSA posted EPS of -0.06 USD versus a -0.09 USD estimate — a beat of 33.3%.
What is KNSA's earnings track record?
Over the last 1 reported quarters with consensus data, KNSA beat estimates 1 times (100%).
What is KNSA's current P/E ratio and EPS?
KNSA trades at a trailing P/E of 63.71 on trailing EPS of 0.9548001618212325 USD.
What do analysts rate KNSA?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 70.2 USD.